ATS Corporation’s fiscal second-quarter report, released November 4, was not pretty by any conventional measure. Revenue fell 8.6% year over year to C$665.8 million. Adjusted earnings per share came in at $0.27, missing consensus by six cents. The company swung to a net loss of $5.0 million from net income of $33.6 million a year earlier. Then management withdrew its prior fiscal 2027 outlook for modest revenue growth and margin expansion, citing delayed orders in packaging and broader customer hesitation as backlog conversion timing stretched. The stock fell about 6% on the day.
That is the near-term picture. The strategic picture looks completely different, and that gap is precisely what makes ATS interesting right now.
The Backlog Tells the Real Story
Beneath the revenue miss sits a record C$1.238 billion life sciences order backlog, the highest in the company’s history since it was founded in 1978. Total backlog stands at C$2.009 billion. Order bookings of C$827 million rose 12.7% year over year. The trailing 12-month book-to-bill ratio is approximately 1.05 to 1. These are not the numbers of a business in structural decline. They are the numbers of a business whose revenue recognition lags its demand by several quarters, particularly in large life sciences factory programs that management acknowledges may take additional time to convert.
The composition of that backlog matters as much as the size. Life sciences remains the biggest component, and within life sciences the company has pointed to radiopharma and medical device automation as key drivers of order activity. In energy, management has described longer-term nuclear growth opportunities, and disclosed that one U.S. facility was expected to be structured as a sale and leaseback following quarter end, with the leaseback intended to support the growth of the nuclear business in the U.S. These are not commoditized markets. Automation in radiopharmaceutical manufacturing and nuclear refurbishment requires years of regulatory experience and design depth that cannot be replicated quickly.
Why the Selloff Creates the Opportunity
ATS shares are down roughly 30% year-to-date. The consensus 12-month analyst target on the Toronto-listed shares sits around the mid-C$30s, against a price that dipped into the mid-C$20s this month. Goldman Sachs is an outlier with a Sell rating and a mid-C$20s target; several other firms have targets in the C$30s to C$40s range.
An industrial conglomerate evaluating ATS does not care about the quarterly EPS miss. It cares about whether it can acquire, at a compressed multiple, a business with deep automation capabilities in life sciences, nuclear, and onshoring-driven industrial markets that are growing structurally. ATS’s disclosures have highlighted labour constraints and reshoring/onshoring as multi-year demand drivers. Those forces are not going away.
What Traders Watch
The 18-month Fixed Cost Transformation Program is the near-term pivot point. Management has begun restructuring actions and has said it is redirecting savings into higher-growth areas, including nuclear. If Q3 revenue, guided at C$640 million to C$680 million, comes in at the top of that range and adjusted margins show any recovery from the 8.6% reported in Q2, the buyout speculation will intensify. At current prices, the math for a strategic acquirer closes. The question is whether one moves before the market figures that out.
